This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Examining Eli Lilly's Jaypirca (pirtobrutinib) in light of the FDA Approval for mantle cell lymphoma
Ticker(s): LLYWho's the expert?
Institution: Pinehurst Medical Clinic
- Medical Oncologist at Pinehurst Medical Clinic; fellowship trained in hematology and oncology at the Naval Medical Center of San Diego/University of Southern California.
- Manages 15 patients with mantle cell lymphoma and 25 patients with WAIHA.
- Extensive background in cancer clinical trials and research with a focus on Bleeding Disorders, Bone Marrow/Stem Cell Transplantation, Leukemia, Lymphoma, Multiple Myeloma, and Myelodysplastic Syndromes.
Interview GoalThis conversation will focus on Eli Lilly's Jaypirca (pirtobrutinib) and it's potential in treating mantle cell lymphoma.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
